Objective To analyze the efficacy of nimodipine combined with edaravone in the treatment of the elderly patients with acute cerebral infarction. Methods From April 2017 to October 2018,6 elderly patients with acute cerebral infarction admitted in our department were recruited, and then randomly divided into study group (n=48) and control group (n=48). The control group was treated with nimodipine and the study group was treated with nimodipine combined with edaravone. The clinical efficacy; score of the National Institutes of Health Stroke scale (NIHSS); blood oxygen indices, such as, oxyhemoglobin (HbO₂), hemoglobin (Hb), pulse oxygen saturation (SpO₂), total hemoglobin (HbT), and oxidative stress response indices, including superoxide dismutase (SOD), malondialdehyde (MDA), high-sensitivity C-reactive protein (hs-CRP), and incidence of adverse reactions were compared between the 2 groups. SPSS statistics 22.0 was used for data analysis. Student′s t test or Chi-square test was employed for the com-parison between groups. Results The total effective rate was statistically higher in the study group than in the control group [95.83%(46/48) vs 75.00%(36/48), χ²=12.080, P＝0.001]. After treatment, the study group had significantly higher HbO₂ [(4.16±0.57)% vs (3.26±0.46)%], SpO₂ [(66.32±5.51)% vs (59.64±4.93)%] and HbT [(4.48±0.86) vs (3.62±0.88)g/L], and obviously lower Hb [(0.42±0.16) vs (0.56±0.22)g/L], SOD [(42.65±6.88) vs (48.56±8.09)U/ml],MDA [(2.28±0.58) vs (3.78±0.85)mmol/L], hs-CRP [(8.12±2.04) vs (12.87±4.26)mg/L] and NIHSS score [(13.13±5.74) vs (18.92±4.60)] when compared with the control group (all P<0.05). The incidence of adverse reactions was lower in the study group than in the control group [16.67%(8/48) vs 39.58%(18/48), χ²=6.235, P=0.013]. Conclusion Nimodipine combined with edaravone is effective in the treatment of elderly patients with acute cerebral infarction.